Relapsed or refractory malignant lymphoma
Conditions
Interventions
Patients receive a single subcutaneous injection of pegfilgrastim (3.6 mg) 2 days after chemotherapy.
Sponsors
National Hospital Organization Kyushu Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Relapsed or refractory non-hodgkins lymphoma and hodgkins lymphoma 2)Age >= 20 years old at informed consent 3)ECOG PS <= 2 4)Patients who are going to receive (R)EPOCH, CHASE(R), (R)DeVIC or (R)ESHAP regimen. 5)Patients who meet the following criteria within 14 days before salvage therapy. Neutrophil count >= 1,000/ul Platelet >= 50,000/ul Total bilirubin level <= 2 times the upper normal limit in institute Serum creatinine <= 1.5mg/dl
Exclusion criteria
Exclusion criteria: 1)Patients who have a possibility of severe infection after the entry or active infection at the entry. 2)Pregnant or breast-feeding females and females who have a possibility of pregnancy. 3)Patients who have any other inadequacy for this study by physicians.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ratio of outpatient management period (days) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Readmission rate due to febrile neutropenia 2) All-cause readmission rate 3) Number of transfusions (RBC, Platelet) 4) Number of outpatient visits 5) Relative dose intensity 6) Cost analysis 7) Utilization rate of antibiotics 8) Patient satisfaction 9) Adverse events | — |
Countries
Japan
Contacts
Public ContactTomoyuki Nukada
Kyowa Kirin Medical Affairs
Outcome results
None listed